Show simple item record

Authordc.contributor.authorValenzuela, Fernando
Authordc.contributor.authorFlores, Rodrigo
Admission datedc.date.accessioned2022-01-10T14:21:31Z
Available datedc.date.available2022-01-10T14:21:31Z
Publication datedc.date.issued2021
Cita de ítemdc.identifier.citationCLINICS 2021;76:e3015es_ES
Identifierdc.identifier.other10.6061/clinics/2021/e3015
Identifierdc.identifier.urihttps://repositorio.uchile.cl/handle/2250/183597
Abstractdc.description.abstractMonoclonal antibodies or fusion proteins, defined as biological drugs, have modified the natural history of numerous immune-mediated disorders, allowing the development of therapies aimed at blocking the pathophysiological pathways of the disease, providing greater efficacy and safety than conventional treatment strategies. Virtually all therapeutic proteins elicit an immune response, producing anti-drug antibodies (ADAs) against hypervariable regions of immunoglobulins. Immunogenicity against biological drugs can alter their pharmacokinetic and pharmacodynamic properties, thereby reducing the efficacy of these drugs. In more severe cases, ADAs can neutralize the therapeutic effects of the drug or cause serious adverse effects, mainly hypersensitivity reactions. The prevalence of ADAs varies widely depending on the type of test used, occurrence of false-negative results, and non-specific binding to the drug, making it difficult to accurately assess their clinical impact. Concomitant use of immunosuppressors efficiently reduces the immunogenicity in a dosedependent manner, either by decreasing the frequency of detectable ADAs or by delaying their appearance, thereby enhancing the effectiveness of biological therapies. Among the new therapeutic strategies for the management of psoriasis, biological agents have gained increasing importance in recent years as they interrupt key inflammation pathways involved in the physiopathology of the disease. Reports regarding ADA in new biologics are still scarce, but the most recent evidence tends to show little impact on the clinical response to the drug, even with prolonged treatment. It is therefore essential to standardize laboratory tests to determine the presence and titles of ADAs to establish their administration and management guidelines that allow the determination of the real clinical impact of these drugs.es_ES
Lenguagedc.language.isoenes_ES
Publisherdc.publisherHospital Clinicas, Brasiles_ES
Type of licensedc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
Link to Licensedc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
Sourcedc.sourceClinicses_ES
Keywordsdc.subjectImmunogenicityes_ES
Keywordsdc.subjectAnti-drug antibodieses_ES
Keywordsdc.subjectAnti-TNFes_ES
Keywordsdc.subjectAnti-IL-12/23es_ES
Keywordsdc.subjectAnti-IL-17es_ES
Keywordsdc.subjectAnti-IL-23es_ES
Títulodc.titleImmunogenicity to biological drugs in psoriasis and psoriatic arthritises_ES
Document typedc.typeArtículo de revistaes_ES
dc.description.versiondc.description.versionVersión publicada - versión final del editores_ES
dcterms.accessRightsdcterms.accessRightsAcceso abiertoes_ES
Catalogueruchile.catalogadorcrbes_ES
Indexationuchile.indexArtículo de publícación WoSes_ES


Files in this item

Icon

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 United States
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 United States